Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Hepatocellular 52Carcinoma, Renal Cell 25Liver Neoplasms 23Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Kidney Neoplasms 11Leukemia, Myeloid, Acute 9Melanoma 8Glioblastoma 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Gliosarcoma 5Urinary Bladder Neoplasms 4Recurrence 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Carcinoma 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leiomyosarcoma 3

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Sarcoma × Sorafenib × Clear all
NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡